3 results
Approved WMOCompleted
To determine the feasibility, toxicity and safety of anti-CEA x anti hapten bispecific antibodies (TF2) and Lu-177-labelled di-HSG-DOTA peptide (IMP-288) in patients with advanced colorectal carcinoma.
Approved WMORecruiting
To demonstrate the superiority of finerenone to placebo in reducing the rate of the composite CV endpoint.To determine superiority of finerenone to placebo for each secondary endpointTo assess the safety and tolerability of finerenone
Approved WMORecruiting
This study is being carried out to investigate the treatment with benralizumab in patients with active HES.The purpose of this study is to see if benralizumab, given as injections under the skin, can help control your HES better if it is added to…